TFAM Antibodies

Background

The TFAM gene encodes A key mitochondrial transcription factor A, which, as a nuclear-encoded protein, mainly exists in the mitochondrial matrix of eukaryotic cells. This protein collaboratively regulates the replication and transcription processes of the mitochondrial genome by specifically binding to and encapsulating mitochondrial DNA, while simultaneously activating the transcription initiation complex. In cellular energy metabolism, TFAM ensures the normal operation of the oxidative phosphorylation system by maintaining the stability of mtDNA. This characteristic makes it have special physiological significance in high-energy-consuming tissues such as myocardial and neural tissues. This gene was first identified by a team of Japanese scientists in the 1980s. Its unique double helix structure and DNA bending mechanism were analyzed through crystal diffraction technology in the 1990s, providing an important model for epigenetic regulation research. As a classic example in the field of mitochondrial nucleoprotein interactions, TFAM has continuously driven the research progress of cellular energy metabolism, epigenetic regulation, and molecular mechanisms related to mitochondrial diseases.

Structure Function Application Advantage Our Products

Structure of TFAM

TFAM is a key mitochondrial protein with a molecular weight of approximately 25 kDa. Due to the differences in the transcription start site and splicing mode, this protein mainly exists in two main isotypes in the human body, and its molecular weight will show slight differences.

Species	Human	Mouse	Rat	Bovine
Molecular Weight (kDa)	About 25	About 24.8	About 24.9	About 25.1
Primary Structural Differences	Contains two HMG-box domains	With the human TFAM highly homologous	Highly conserved sequence	Functional structure similar domain

This protein is encoded by the nuclear genome and contains a mitochondrial targeting sequence to guide its transport to the mitochondrial matrix. The core functional domain of TFAM contains two high mobility family (HMG-box) domains, a feature that enables it to bind and bend mitochondrial DNA double strands in a sequentially non-specific manner. Its tertiary structure forms a unique molecular clip, which tightly wraps mtDNA through extensive interactions with the DNA skeleton via two HMG-box domains, thereby compressing the genome and initiating the transcription process.

Fig. 1:Overall structure of the asymmetric unit of TFAM-NS2. Fig. 1 Overall structure of the asymmetric unit of TFAM-NS2.¹

Key structural properties of TFAM:

Double HMG-box domains constitute the core DNA binding unit
Flexible junction area gives conformation plasticity
Basic amino acid rich regions mediate nonspecific DNA winding

Functions of TFAM

The core function of the TFAM gene is to regulate the replication and transcription of mitochondrial DNA. In addition, it is also involved in multiple cellular physiological activities, including maintaining genomic stability and regulating apoptosis.

Function	Description
Transcriptional activation	Binding to the promoter region of mitochondrial DNA, RNA polymerases are recruited to form transcription initiation complexes.
Genome compression	Wrap and bend mitochondrial DNA in a sequence-independent manner, compressing it into a nucleoid structure.
Damage protection	Protect the fragile mitochondrial DNA from free radical attacks through physical coverage and maintain genomic integrity.
Apoptosis regulation	During cellular stress, the release of TFAM can act as a signaling molecule and participate in the initiation of the apoptotic signaling pathway.
Energy metabolism hub	By controlling the transcription of oxidative phosphorylation-related subunits, the level of cellular energy production is directly regulated.

Unlike typical transcription factors, TFAM regulates mitochondrial gene expression in a "dose-dependent" manner - the number of its binding to DNA directly determines the level of transcriptional activity. This unique regulatory mechanism makes it a key molecular hub connecting nuclear gene expression and mitochondrial function.

Applications of TFAM and TFAM Antibody in Literature

1. Zhao, Meng, et al. "Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance." Theranostics 11.4 (2021): 1845. https://doi.org/10.7150/thno.50905

The article indicates that in renal ischemia-reperfusion injury, mitochondrial reactive oxygen species inhibit the expression of the transcription factor TFAM and promote its degradation, leading to mitochondrial DNA damage, energy metabolism disorders and intensified inflammatory responses. TFAM deficiency is a key mechanism promoting kidney injury.

2. Kozhukhar, Natalya, and Mikhail F. Alexeyev. "35 years of TFAM research: old protein, new puzzles." Biology 12.6 (2023): 823. https://doi.org/10.3390/biology12060823

The article indicates that TFAM is a key protein for the maintenance and expression of mitochondrial DNA. This article reviews its 35-year research and points out that its functions are complex and diverse, and some of the conclusions are even contradictory. The latest structural research has brought new insights and raised new questions, which urgently need in-depth exploration to promote the development of the field.

3. Chen, Sisi, et al. "Depressed TFAM promotes acetaminophen-induced hepatotoxicity regulated by DDX3X–PGC1α–NRF2 signaling pathway." Molecular Medicine 30.1 (2024): 246. https://doi.org/10.1186/s10020-024-01017-0

The article indicates that in drug-induced liver injury, DDX3X inhibits the expression of TFAM through the PGC-1α/NRF-2 signaling pathway. The absence of TFAM leads to mitochondrial dysfunction, while increasing the level of TFAM can effectively alleviate liver injury, revealing its key protective effect.

4. Del Rey, Manuel J., et al. "TFAM-deficient mouse skin fibroblasts–an ex vivo model of mitochondrial dysfunction." Disease Models & Mechanisms 14.8 (2021): dmm048995. https://doi.org/10.1242/dmm.048995

Researchers specifically knocked out TFAM in skin fibroblasts and successfully established a mitochondrial dysfunction model. TFAM deficiency leads to impaired mtDNA expression, reduction of respiratory chain complexes and mitochondrial failure, and triggers cellular senescence and pro-inflammatory phenotypes.

5. Bruno, Giuseppina, et al. "TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells." Journal of Molecular Medicine 102.10 (2024): 1285-1296. https://doi.org/10.1007/s00109-024-02479-9

The article indicates that in colorectal cancer, the molecular chaperone TRAP1 negatively regulates mitochondrial biosynthesis by inhibiting the PGC-1α/TFAM signaling pathway. Silencing TRAP1 can enhance mitochondrial quality and DNA copy number, promoting the transformation of cellular metabolism to oxidative phosphorylation.

Creative Biolabs: TFAM Antibodies for Research

Creative Biolabs specializes in the production of high-quality TFAM antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

Custom TFAM Antibody Development: Tailor-made solutions to meet specific research requirements.
Bulk Production: Large-scale antibody manufacturing for industry partners.
Technical Support: Expert consultation for protocol optimization and troubleshooting.
Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our TFAM antibodies, custom preparations, or technical support, contact us at email.

Reference

Choi, Woo Suk, and Miguel Garcia-Diaz. "A minimal motif for sequence recognition by mitochondrial transcription factor A (TFAM)." Nucleic Acids Research 50.1 (2022): 322-332. https://doi.org/10.1093/nar/gkab1230